Tags

Type your tag names separated by a space and hit enter

Thromboxane A2 synthetase inhibitor (OKY-046) improves abnormal mucociliary transport in asthmatic patients.
Ann Allergy 1992; 68(1):53-6AA

Abstract

The effect of a thromboxane A2 synthetase inhibitor (OKY-046, 400 mg po/day) on mucociliary transport was investigated in 19 asthmatic patients. The nasal clearance time, as measured by the saccharin test, was prolonged in asthmatics (60.2 +/- 8.4 SE min) compared with normal controls (15.1 +/- 3.4 SE min). Within 4 weeks after OKY-046 administration, the nasal clearance time had improved (27.4 +/- 4.4 SE min, P less than .01) and the amount of sputum had decreased 30% (P less than .01). These results indicate that thromboxane A2 plays an important role in mucociliary transport in patients with asthma.

Authors+Show Affiliations

Ishikawa Prefectural Central Hospital, Kanazawa, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

1736720

Citation

Kurashima, K, et al. "Thromboxane A2 Synthetase Inhibitor (OKY-046) Improves Abnormal Mucociliary Transport in Asthmatic Patients." Annals of Allergy, vol. 68, no. 1, 1992, pp. 53-6.
Kurashima K, Ogawa H, Ohka T, et al. Thromboxane A2 synthetase inhibitor (OKY-046) improves abnormal mucociliary transport in asthmatic patients. Ann Allergy. 1992;68(1):53-6.
Kurashima, K., Ogawa, H., Ohka, T., Fujimura, M., & Matsuda, T. (1992). Thromboxane A2 synthetase inhibitor (OKY-046) improves abnormal mucociliary transport in asthmatic patients. Annals of Allergy, 68(1), pp. 53-6.
Kurashima K, et al. Thromboxane A2 Synthetase Inhibitor (OKY-046) Improves Abnormal Mucociliary Transport in Asthmatic Patients. Ann Allergy. 1992;68(1):53-6. PubMed PMID: 1736720.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Thromboxane A2 synthetase inhibitor (OKY-046) improves abnormal mucociliary transport in asthmatic patients. AU - Kurashima,K, AU - Ogawa,H, AU - Ohka,T, AU - Fujimura,M, AU - Matsuda,T, PY - 1992/1/1/pubmed PY - 1992/1/1/medline PY - 1992/1/1/entrez SP - 53 EP - 6 JF - Annals of allergy JO - Ann Allergy VL - 68 IS - 1 N2 - The effect of a thromboxane A2 synthetase inhibitor (OKY-046, 400 mg po/day) on mucociliary transport was investigated in 19 asthmatic patients. The nasal clearance time, as measured by the saccharin test, was prolonged in asthmatics (60.2 +/- 8.4 SE min) compared with normal controls (15.1 +/- 3.4 SE min). Within 4 weeks after OKY-046 administration, the nasal clearance time had improved (27.4 +/- 4.4 SE min, P less than .01) and the amount of sputum had decreased 30% (P less than .01). These results indicate that thromboxane A2 plays an important role in mucociliary transport in patients with asthma. SN - 0003-4738 UR - https://www.unboundmedicine.com/medline/citation/1736720/Thromboxane_A2_synthetase_inhibitor__OKY_046__improves_abnormal_mucociliary_transport_in_asthmatic_patients_ L2 - https://medlineplus.gov/asthma.html DB - PRIME DP - Unbound Medicine ER -